BioNTech SE - ADR

+2.80 (+1.55%)
Products, Strategic Combinations

Genmab And BioNTech Expand Global Strategic Collaboration To Develop And Commercialize Novel Immunotherapy Candidates

Published: 08/05/2022 10:52 GMT
BioNTech SE - ADR (BNTX) - Genmab and Biontech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates.
Genmab and Biontech Will Continue to Share Costs and Potential Future Profits on a 50:50 Basis.
First Monospecific Antibody Candidate Gen1053/bnt313 Planned to Enter Clinical Trials by End of 2022.
Under Terms of Agreement, Companies Will Equally Share Development Costs and Potential Future Profit Deriving From Gen1053/bnt313.